
“Omaxe's launches signal fightback amid balance sheet bleed.”
No clear market view today
The signals we track (volume, delivery, price trend, deals, breadth and flows) aren't aligned for OMAXE today. That isn't bearish, just inconclusive.
50-day SMA is above 200-day SMA (bullish long-term trend)
India-specific risk checks.
Four fundamentals lenses on the company itself: valuation, growth, returns & margins, and financial health, judged against the stock's sector. A separate read from the Market Setup above.
Trading at attractive valuations
₹1,000 invested here buys about ₹217 of annual profit. A cheaper stock would buy more.
Growth is soft or negative
Weak returns and margins
Not enough data to score this factor
Data as of 17 Sept 2026, 9:32 pm